Cargando…
Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes
Administration of low-dose interleukin-2 (IL-2) alone or combined with rapamycin (RAPA) prevents hyperglycemia in NOD mice. Also, low-dose IL-2 cures recent-onset type 1 diabetes (T1D) in NOD mice, partially by boosting pancreatic regulatory T cells (T(reg) cells). These approaches are currently bei...
Autores principales: | Baeyens, Audrey, Pérol, Louis, Fourcade, Gwladys, Cagnard, Nicolas, Carpentier, Wassila, Woytschak, Janine, Boyman, Onur, Hartemann, Agnès, Piaggio, Eliane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749335/ https://www.ncbi.nlm.nih.gov/pubmed/23670972 http://dx.doi.org/10.2337/db13-0214 |
Ejemplares similares
-
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells
por: Grinberg-Bleyer, Yenkel, et al.
Publicado: (2010) -
Role of Cytokines in Thymus- Versus Peripherally Derived-Regulatory T Cell Differentiation and Function
por: Goldstein, Jérémie David, et al.
Publicado: (2013) -
Loss of immune tolerance to IL-2 in type 1 diabetes
por: Pérol, Louis, et al.
Publicado: (2016) -
An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer
por: Sahin, Dilara, et al.
Publicado: (2020) -
Fetal Pancreas Transplants Are Dependent on Prolactin for Their Development and Prevent Type 1 Diabetes in Syngeneic but Not Allogeneic Mice
por: Fourcade, Gwladys, et al.
Publicado: (2013)